Edition:
United States

Haemonetics Corp (HAE)

HAE on New York Consolidated

30.32USD
29 Jul 2016
Change (% chg)

$0.48 (+1.61%)
Prev Close
$29.84
Open
$29.77
Day's High
$30.41
Day's Low
$29.77
Volume
525,597
Avg. Vol
394,760
52-wk High
$40.69
52-wk Low
$25.98

Summary

Name Age Since Current Position

Richard Meelia

66 2011 Non-Executive Independent Chairman of the Board

Christopher Simon

52 2016 President, Chief Executive Officer

Thomas McCurdy

2015 President - Global Plasma

Byron Selman

2015 President - Global Markets

David Helsel

51 2013 Executive Vice President - Global Manufacturing

Jonathan White

55 2013 Chief Science and Technology Officer

Dan Goldstein

2016 Principal Accounting Officer

Sandra Jesse

62 2011 Vice President, Chief Legal Officer

Ronald Gelbman

67 2016 Director

Charles Dockendorff

61 2014 Independent Director

Susan Foote

68 2004 Independent Director

Pedro Granadillo

68 2004 Independent Director

Mark Kroll

62 2006 Independent Director

Ronald Merriman

71 2005 Independent Director

Biographies

Name Description

Richard Meelia

Mr. Richard J. Meelia is Non-Executive Independent Chairman of the Board of Haemonetics Corporation. Mr. Meelia,joined the Board of Directors and assumed the role of Chairman in 2011. He is currently a principal of Meelia Ventures, LLC, a private equity firm focused on early stage healthcare companies. Mr. Meelia is also currently a member of several charitable Boards including Tufts Medical Center and St. Anselm College. He also currently serves as the Chairman of the Board of Apollo Endosurgery, Inc., a private company focused on the development of devices that advance therapeutic endoscopy.From July 2007 until his retirement in July 2011, Mr. Meelia served as Chairman, President, and Chief Executive Officer of Covidien plc following its separation from Tyco International in June, 2007. From January 2006 through the separation, Mr. Meelia was the Chief Executive Officer of Tyco Healthcare and from 1995 through the separation, Mr. Meelia was also the President of Tyco Healthcare. Mr. Meelia joined Kendall Healthcare Products Company, the foundation of both the Tyco Healthcare Business and Covidien, as Group President in 1991. He became President of Tyco Healthcare in 1995. Mr. Meelia formerly served on the Haemonetics Board from 2005-2009. He resigned to focus on his CEO responsibilities at Covidien. Early in his career, Mr. Meelia was promoted through a series of sales and marketing positions at the Pharmaseal and McGaw divisions of American Hospital Supply, where he ultimately became Vice President of Sales and Marketing. Following his career at American Hospital Supply, and before joining Kendall Healthcare, Mr. Meelia was President of Infusaid, Inc. a $30 million division of Pfizer that marketed implantable infusion pumps and ports.

Christopher Simon

Mr. Christopher Simon has been appointed as President, Chief Executive Officer of the Company., effective 16 May 2016. He is currently serves as a Senior Partner of McKinsey & Company in Global Medical Products Practice. Mr. Simon has been a consultant with McKinsey & Company since 1993, and prior to that, he served in commercial roles with Baxter Healthcare Corporation. He has recently been the Lead Partner for McKinsey & Company’s current strategy review with Haemonetics.

Thomas McCurdy

Mr. Thomas McCurdy is President - Global Plasma of the Company. He was President, North America Patient Sales of teh Company since 2010.

Byron Selman

Mr. Byron Selman is President - Global Markets of the Company. Byron Selman , who joined the Company upon the acquisition of Pall Corporation's transfusion medicine business in 2012, is appointed to the position of President, Global Markets. Mr. Selman will oversee the Company's global commercial and market development efforts, with the exception of the Company's commercial Plasma business.

David Helsel

Mr. David D. Helsel is an Executive Vice President - Global Manufacturing of Haemonetics Corporation. He joined Haemonetics as Vice President of Global Manufacturing in March 2012, and is responsible for worldwide oversight of the Company’s manufacturing and supply chain organizations. Mr. Helsel was previously with Covidien, Ltd. for 16 years, where he most recently was Vice President of Operations for the Surgical Solutions global business unit. During his tenure with Covidien, his previous roles included Vice President of Operations for the Medical Supplies segment and Global Director of Operational Excellence – Manufacturing. Mr. Helsel holds a Bachelor of Science degree in Mechanical Engineering from LeTourneau University.

Jonathan White

Dr. Jonathan White is Chief Science and Technology Officer of Haemonetics Corporation. Dr. White joined Haemonetics in 2008 as Vice President of Research and Development. Dr. White joined Haemonetics from Pfizer where he held a number of roles including Chief Information Officer. He previously worked at McKinsey and Company in New York. Dr. White is a Fellow of the Royal College of Surgery in England.

Dan Goldstein

Mr. Dan Goldstein is Principal Accounting Officer of the Company. Prior to joining the Company, Mr. Goldstein was Vice President Technical Accounting and Advisory Services for Covidien PLC, a global health care products company. At Covidien, Mr. Goldstein had previously held the roles of Business Unit Controller, Sustainable Technologies and Director, Corporate Reporting. Prior to Covidien, Mr. Goldstein held positions at EMC Corporation and Calpine Corporation; and he began his career with PricewaterhouseCoopers. He holds a B.A. in Economics from the University of Michigan, Ann Arbor, and is a Certified Public Accountant.

Sandra Jesse

Ms. Sandra Jesse is Vice President, Chief Legal Officer of Haemonetics Corporation., since September 2011. She is responsible for the company’s world-wide Legal, Compliance and Corporate Audit and Controls groups. Ms. Jesse was previously the Executive Vice President and Chief Legal Officer of Blue Cross Blue Shield of Massachusetts, a Partner in the Boston law firm of Choate, Hall and Stewart, and Press Secretary for United States Congressman, Lee Hamilton. She has served on a number of Boards of Directors, including the New England Legal Foundation, Longy School of Music, Boston Harbor Island Alliance and the Landmark School. Ms. Jesse is a former President of the Boston Bar Foundation.

Ronald Gelbman

Mr. Ronald G. Gelbman is Director of the Company. He has resigned from the position of Interim Chief Executive Officer of the Company., effective 16 May 2016. Mr. Gelbman joined the Board of Directors in 2000 and serves on the Audit Committee and is Chairman of the Governance and Compliance Committee. He is currently a member of several Boards including Sarasota Memorial Healthcare Foundation, a not for profit public health organization, SunTrust Southwest Florida Board of Advisors and Clockwork Home Services, Inc., a private home services company. He is a member of the Board of Trustees at Rollins College and the Out-of-Door Academy College Preparatory School.Mr. Gelbman retired from Johnson & Johnson in April 2000, after serving as Worldwide Chairman of the Health Systems and Diagnostics Group. He was also a member of the executive committee of Johnson & Johnson. Mr. Gelbman began his career with Johnson & Johnson in 1972, serving in various senior level positions throughout the company.

Charles Dockendorff

Mr.Charles J.Dockendorff is currently the director of the company.Mr. Dockendorff is a highly-respected healthcare industry leader with extensive experience in finance and corporate management. As a retired global executive of one of the world’s largest healthcare products companies, Mr. Dockendorff brings to the Board many years of leadership experience in financial management and planning.Mr. Dockendorff, joined the Board of Directors in 2014 and is Chairman of the Audit Committee. He currently serves as a member of the Keysight Technologies Inc. Board of Directors where he is Chairman of the Audit and Finance Committee and a member of the Nominating and Corporate Governance Committee. Keysight Technologies is a New York Stock Exchange listed company focused on electronic measurement. Mr. Dockendorff joined the Board of Directors of Boston Scientific Corporation in April, 2015 and serves on the audit and finance committees.In 2015, Mr. Dockendorff retired from Covidien plc, a leading $10 billion global healthcare products company, where he had previously served as Executive Vice President and Chief Financial Officer (CFO) since 2006. The business, formerly known as Tyco Healthcare, separated from parent company Tyco International on June 29, 2007. From 1995 until 2006, Mr. Dockendorff served as Vice President and Chief Financial Officer of Covidien. Mr. Dockendorff joined the Kendall Healthcare Products Company, the foundation of the Tyco Healthcare business, in 1989 as Controller and was named Vice President and Controller five years later. He was appointed CFO of Tyco Healthcare in 1995, and helped the Company grow from $600 million in 1995 to $10 billion as Covidien in 2007.Before joining Kendall/Tyco Healthcare, Mr. Dockendorff was the CFO, Vice President of Finance and Treasurer of Epsco, Inc. and Infrared Industries, Inc. In addition, Mr. Dockendorff worked as an accountant for Arthur Young & Company and the General Motors Corporation

Susan Foote

Ms. Susan Bartlett Foote is an Independent Director of Haemonetics Corporation. From 2009 to Present, Professor Emeritus, Division of Health Policy and Management for the School of Public Health, University of Minnesota. From 1999 to 2009, Professor, Division of Health Policy and Management, School of Public Health, University of Minnesota. 1999 to 2006, Associate Professor and from 1999 to 2005 Division Head and from 1996 to 1999, President, Public Policy Partners, a health policy consulting firm. From 1995 a Partner in the law firm of Dorsey & Whitney. From 1991 to 1994, a Senior Health Policy Analyst for the United States Senate and from 1982 to 1993, Associate Professor of Business & Public Policy at the University of California at Berkeley. Currently, member of the California State Bar Association; board of Directors of Banner Health; and Board Member of the Medical Technology Leadership Forum.

Pedro Granadillo

Mr. Pedro P. Granadillo is an Independent Director of Haemonetics Corporation.Mr. Granadillo is a highly-respected pharmaceutical industry leader with extensive experience in corporate management. Having served as a global executive of one of the world’s largest pharmaceutical companies, Mr. Granadillo brings to the Board, many years of leadership experience in manufacturing operations, quality and human resources.Mr. Granadillo,joined the Board of Directors in 2004 and serves as Chairman of the Compensation Committee and is a member of the Governance and Compliance Committee. Until its acquisition by Shire plc in February, 2015, Mr. Granadillo was a member of the Board and served as its Chairman of the Compensation Committee at NPS Pharmaceuticals, Inc., a public biotechnology company. Mr. Granadillo co-founded and is a director of Umbria Pharmaceuticals, a private pharmaceutical company.Mr. Granadillo resigned as director of Nile Therapeutics, a public pharmaceutical company in December, 2013 and from Dendreon Corporation, a public biotechnology company in March 2014. He is the former Senior Vice President of Eli Lilly and Company with world-wide responsibility for manufacturing, quality and human resources. Mr. Granadillo retired from Eli Lilly and Company in 2004 after 34 years of dedicated service. He was a member of Eli Lilly’s Executive Committee and held various senior level positions during his tenure there including 13 years in Europe.

Mark Kroll

Dr. Mark W. Kroll, Ph.D., is an Independent Director of Haemonetics Corporation. Dr. Kroll, a well-known pioneer in the field of electrical medical devices and distinguished technology expert throughout the global medical device industry, provides the Board with extensive expertise in the areas of medical innovation and technology. In 2010, Dr. Kroll was awarded the Career Achievement Award in Biomedical Engineering, the highest international award in biomedical engineering.Dr. Kroll, joined the Board of Directors in 2006 and serves on the Compensation Committee. He is currently a member of the Board of Directors of TASER International, Inc., a public safety technologies company, and is an Adjunct Full Professor of Biomedical Engineering at the University of Minnesota.Dr. Kroll most recently served as Chairman of the Board of Directors at New Cardio, Inc., a public cardiac diagnostic and services company from 2008 until 2011. Dr. Kroll served as the Senior Vice President and Chief Technology Officer for the Cardiac Rhythm Managemendivision of St. Jude Medical Inc. He also served as Vice President of the Tachycardia Business division and in various senior executive roles within St. Jude from 1995 through his retirement in 2005. Dr. Kroll also served as an Adjunct Full Professor of Biomedical Engineering and Lecturer on Cardiovascular Physiology at California Polytechnic University. He has more than 25 years’ experience with cardiovascular devices and instrumentation and is the named inventor of more than 350 U.S. patents as well as numerous international patents.

Ronald Merriman

Mr. Ronald L. Merriman is an Independent Director of Haemonetics Corporation. Having served as Vice Chair and Partner of KPMG, a global accounting and consulting firm, Mr. Merriman brings the Board extensive expertise in financial management, enterprise risk management and operational controls and effectiveness as well as extensive public company audit committee experience.Mr. Merriman, joined the Board of Directors in 2005 and is a member of the Audit Committee. He is currently a member of the Board of Directors, Chair of the Audit Committee and member of the Compensation Committee of Aircastle Limited, a public aircraft leasing company. He also serves as member of the Board of Directors and Chair of the Audit and Finance Committee of Pentair plc., a public global diversified industrial company, and is a member of the Board of Directors and Chairman of the Audit Committee and member of both the Nominating and Corporate Governance and Strategic Planning Committees of Realty Income Corporation, a public real estate investment trust.More recently, from 2003 to 2011, Mr. Merriman was the Managing Director of Merriman Partners, a management advisory firm he founded. From 1967 to 1997 Mr. Merriman served at KPMG where he was Vice Chair, Senior Partner for its global healthcare and life sciences practice, Chief Operating Officer of its Health Care and Life Sciences Business Segment and member of the Executive Management Committee. From 1997 to 1999, he served as Executive Vice President of Ambassador International, Inc., a publicly traded travel services business. He has also held leadership positions at various other firms including Managing Director of O'Melveny & Myers and Executive Vice President of Carlson Wagonlit Travel.